Health Care Equipment & Supplies · Nasdaq

PODDInsulet Corp

Last close
$152.48 +2.1%
52-week range
$126.40 to $354.88
Market cap
$10.6B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$2.71B
+31% vs FY24
Net income
$247M
-41% vs FY24
Free cash flow
$378M
+24% vs FY24
Net cash
-$233M
Cash $716M, debt $949M

Stock price

+305% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
25.0x
21.4x4,955x
3rd percentile, below its median of 413x
Positive-earnings quarters only
Price / sales
3.3x
2.8x17.4x
4th percentile, below its median of 8.7x
EV / EBITDA
15.8x
13.6x1,042x
2nd percentile, below its median of 132x
Price / free cash flow
40.7x
34.9x1,774x
20th percentile, below its median of 66.8x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
25.0x
Earnings yield
4.0%
Price / sales
3.3x
Price / book
6.7x
Price / operating cash flow
20.8x
EV / EBITDA
15.8x
EV / sales
3.4x
Free cash flow yield
2.5%

Profitability

Gross margin
71.9%
Operating margin
18.4%
Net margin
13.4%
Return on equity
27.2%
Return on capital
18.1%

Growth per year

Revenue, 3 years
+27.5%
Revenue, 5 years
+24.5%
Revenue, 9 years
n/aNot reported
EPS, 3 years
+268%

Balance sheet

Cash and investments
$584M
Total debt
$962M
Net cash
-$378M
Debt / equity
0.61x
Current ratio
2.51x

Shares and dividend

Shares outstanding
69.4M
Share count, 5 years
+9.0%
Beta, 1 year
0.44
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $842M
RevenueNet income
Gross profitLatest quarter $632M
EBITDALatest quarter $218M
Margins75 / 23 / 17%
GrossOperatingNet
Earnings per shareLatest quarter $2.03
Cash flowLatest quarter $124M
OperatingCapexFree
Cash vs debtLatest quarter $584M
Cash and investmentsTotal debt
P/E historyNow 25.0x
P/E, median 413x dashed
P/S historyNow 3.3x
P/S, median 8.7x dashed

Where the revenue comes from

Drug Delivery went from 4% to 1% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

U S OmnipodInternational OmnipodDrug Delivery
FY22
68%28%
$1.31B
FY23
74%24%
$1.70B
FY24
73%25%
$2.07B
FY25
71%28%
$2.71B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
U S Omnipod$1.92B70.9%+27%
International Omnipod$754M27.9%+44%
Drug Delivery$34.1M1.3%-12%

Health Care Equipment & Supplies peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ABT Abbott Laboratories $188B +10% 13.8%40.4x3.9x 60th percentile
DHR Danaher Corp $164B +6% 20.4%38.1x6.4x 65th percentile
ISRG Intuitive Surgical Inc $154B +20% 28.4%53.7x13.3x 48th percentile
MDT Medtronic plc $132B +10% 18.1%25.3x3.5x 20th percentile
SYK Stryker Corp $118B +8% 20.7%33.0x4.5x 30th percentile
PODD Insulet Corp $10.6B +26% 18.4%25.0x3.3x 3rd percentile

The company

Sector
Health Care
Industry
Health Care Equipment & Supplies
Headquarters
Acton, MA
Fiscal year ends
December

Around the numbers

What the rest of EdgeStacker knows about PODD.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 449 active funds. Crowd level: quiet.

Open the Smart money tab